Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Pfizer’s Tanezumab REMS Faces US FDA Doubts Heading Into Panel Review
Mar 23 2021
•
By
Sue Sutter
Osteoarthritis progression leading to total joint replacement is among the safety issues flagged in FDA's review of tanezumab. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from US FDA Performance Tracker
More from Regulatory Trackers